Original Research Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment

Autor: M. PROVENCIO, R. SERNA-BLASCO, F. FRANCO, V. CALVO, A. ROYUELA, M. AUGLYTE, A. SANCHEZ-HERNANDEZ, M. CAMPAYO, C. GARCIA-GIRON, M. DOMINE, A. BLASCO, J. SANCHEZ, J. ORAMAS, J. BOSCH-BARRERA, M. SALA, M. SERENO, A. ORTEGA, L. CHARA, B. HERNANDEZ, A. PADILLA, J. COVES, R. BLANCO, J. BALSALOBRE, X. MIELGO, C. BUENO, E. JANTUS-LEWINTRE, M. MOLINA-VILA, A. ROMERO
Rok vydání: 2021
Předmět:
Zdroj: EUROPEAN JOURNAL OF CANCER
r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
instname
r-CIPF: Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
Centro de Investigación Principe Felipe (CIPF)
ISSN: 0959-8049
Popis: Background: Survival data support the use of first-line osimertinib as the standard of care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). However, it remains unclear whether upfront osimertinib is superior to sequential first-or second-generation tyrosine kinase inhibitors (TKIs) followed by osimertinib for all patients. It is impossible to predict which patients are at high risk of progression, and this constitutes a major limitation of the sequential TKI approach. Patients and methods: A total of 830 plasma samples from 228 patients with stage IV, EGFR-positive NSCLC who were treated with first-line TKIs were analysed by digital polymerase chain reaction (dPCR). Results: The circulating tumour DNA (ctDNA) levels helped to identify patients with significantly improved survival rate, regardless of the treatment. Patients treated with first-or second-generation TKIs (N = 189) with EGFR mutations in plasma at a mutant allele frequency (MAF)
Databáze: OpenAIRE
Externí odkaz: